The top pharma companies by revenue 2018New analysis from GlobalData has revealed the top 20 pharma companies by revenue for 2018, with Johnson & Share XThe top pharma companies by revenue 2018https://pharmaphorum.com/views-and-analysis/the-top-pharma-companies-by-revenue-2018/
Celgene strikes $1.5bn cell therapy deal with ImmaticsCelgene shows no sign of slowing down on the deal-making front as its merger with Bristol-Myers Squibb draws Share XCelgene strikes $1.5bn cell therapy deal with Immaticshttps://pharmaphorum.com/news/celgene-strikes-1-5bn-cell-therapy-deal-with-immatics/
Amgen stumps up $13.4bn to claim Otezla from CelgeneCelgene has the buyer it needed for Otezla, smoothing the way for its mega-merger with Bristol-Myers Squibb. Amgen Share XAmgen stumps up $13.4bn to claim Otezla from Celgenehttps://pharmaphorum.com/news/amgen-stumps-up-13-4bn-to-claim-otezla-from-celgene/
Celgene scores regulatory win ahead of BMS mergerCelgene has scored a major regulatory win ahead of its proposed merger with Bristol-Myers Squibb, with the FDA Share XCelgene scores regulatory win ahead of BMS mergerhttps://pharmaphorum.com/news/celgene-scores-regulatory-win-ahead-of-bms-merger/
Celgene gets new approval for soon-to-be-shed OtezlaCelgene has picked up a third approval for its anti-inflammatory drug Otezla, although it won’t reap much commercial Share XCelgene gets new approval for soon-to-be-shed Otezlahttps://pharmaphorum.com/news/celgene-gets-new-approval-for-soon-to-be-shed-otezla/
BMS will shed Otezla to push Celgene takeover throughBristol-Myers Squibb has opted to divest big-selling psoriasis drug Otezla to smooth the passage of its $74 billion Share XBMS will shed Otezla to push Celgene takeover throughhttps://pharmaphorum.com/news/bms-will-shed-otezla-to-push-celgene-takeover-through/
Celgene gets MS blockbuster-in-waiting ozanimod back on trackRegulators in the US and EU have formally started their review of Celgene’s oral drug ozanimod for multiple Share XCelgene gets MS blockbuster-in-waiting ozanimod back on trackhttps://pharmaphorum.com/news/celgene-gets-ms-blockbuster-in-waiting-ozanimod-back-on-track/
BMS reveals its post-Celgene takeover management teamBristol-Myers Squibb has announced its new-look leadership after the Celgene takeover goes through, and it reveals a mixed Share XBMS reveals its post-Celgene takeover management teamhttps://pharmaphorum.com/news/bms-post-celgene-takeover-management-team/
Celgene gets speedy review for thalassaemia drug luspaterceptIt’s shaping up to be a landmark year for the community of patients with rare blood disorder beta Share XCelgene gets speedy review for thalassaemia drug luspatercepthttps://pharmaphorum.com/news/celgene-gets-speedy-review-for-thalassaemia-drug-luspatercept/
